Intestinal Secretory Mechanisms in Irritable Bowel Syndrome-Diarrhea

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 6, 2015, Pages 1051-1057

  Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

Absorption; Intestine; Pathogenesis; SCFA

Indexed keywords

ALOSETRON; AMINE; BILE ACID; CHROMOGRANIN; GASTROINTESTINAL POLYPEPTIDE; GUANYLATE CYCLASE; GUANYLATE CYCLASE 2B RECEPTOR; GUANYLATE CYCLASE C; HISTAMINE; NEUROPEPTIDE Y; ONDANSETRON; PEPTIDE YY; PURINE DERIVATIVE; RAMOSETRON; RECEPTOR; SECRETOGRANIN; SEROTONIN; SHORT CHAIN FATTY ACID; SOMATOSTATIN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CHLORIDE DIARRHEA; COLON MUCOSA; DIARRHEA; ENTEROENDOCRINE CELL; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INTESTINAL SECRETION; INTESTINE INNERVATION; INTESTINE TRANSIT TIME; IRRITABLE COLON; JEJUNUM MUCOSA; PATHOPHYSIOLOGY; PATIENT CARE; SEROTONIN METABOLISM; ANIMAL; GASTROINTESTINAL MOTILITY; INTESTINAL SECRETIONS; PATHOLOGY;

ANIMALS; DIARRHEA; GASTROINTESTINAL MOTILITY; HUMANS; INTESTINAL SECRETIONS; IRRITABLE BOWEL SYNDROME;

EID: 84930380712     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.07.020     Document Type: Article

References (84)

1. Spiller R., Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009, 136:1979-1988.
2. Field M. Intestinal ion transport and the pathophysiology of diarrhea. JClin Invest 2003, 111:931-943.
3. Vassallo M., Camilleri M., Phillips S.F., et al. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 1992, 102:102-108.
4. Steens J., Van Der Schaar P.J., Penning C., et al. Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome. Neurogastroenterol Motil 2002, 14:241-247.
5. Simrén M., Abrahamsson H., Björnsson E.S. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 2001, 48:20-27.
6. Kidd M., Modlin I.M., Gustafsson B.I., et al. Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants. Am J Physiol 2008, 295:G260-G272.
7. Peregrin A.T., Ahlman H., Jodal M., et al. Involvement of serotonin and calcium channels in the intestinal fluid secretion evoked by bile salt and cholera toxin. Br J Pharmacol 1999, 127:887-894.
8. Spiller R.C. Effects of serotonin on intestinal secretion and motility. Curr Opin Gastroenterol 2001, 17:99-103.
9. Gershon M.D., Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007, 132:397-414.
10. Hoffman J.M., Tyler K., Maceachern S.J., et al. Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 2012, 142:844-854.
11. Mawe G.M., Hoffman J.M. Serotonin signalling in the gut: functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 2013, 10:473-486.
12. Atkinson W., Lockhart S., Whorwell P.J., et al. Altered 5 hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006, 130:34-43.
13. Houghton L.A., Atkinson W., Whitaker R.P., et al. Increased platelet depleted plasma 5 hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003, 52:663-670.
14. Dunlop S.P., Coleman N.S., Blackshaw E., et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005, 3:349-357.
15. Bellini M., Rappelli L., Blandizzi C., et al. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. Am J Gastroenterol 2003, 98:2705-2711.
16. Franke L., Schmidtmann M., Riedl A., et al. Serotonin transporter activity and serotonin concentration in platelets of patients with irritable bowel syndrome: effect of gender. JGastroenterol 2010, 45:389-398.
17. Foley S., Garsed K., Singh G., et al. Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology 2011, 140:1434-1443.
18. Coates M.D., Mahoney C.R., Linden D.R., et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004, 126:1657-1664.
19. Faure C., Patey N., Gauthier C., et al. Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology 2010, 139:249-258.
20. Donowitz M., Binder H.J. Jejunal fluid and electrolyte secretion in carcinoid syndrome. Am J Dig Dis 1975, 20:1115-1122.
21. von der Ohe M., Camilleri M., Kvols L.K., et al. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. NEngl J Med 1993, 329:1073-1078.
22. Spiller R.C., Jenkins D., Thornley J.P., et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000, 47:804-811.
23. Lincoln J., Crowe R., Kamm M.A., et al. Serotonin and 5-hydroxyindoleacetic acid are increased in the sigmoid colon insevere idiopathic constipation. Gastroenterology 1990, 98:1219-1225.
24. Miwa J., Echizen H., Matsueda K., et al. Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits. Digestion 2001, 63:188-194.
25. Zhao R.H., Baig M.K., Thaler K.J., et al. Reduced expression of serotonin receptor(s) in the left colon of patients with colonic inertia. Dis Colon Rectum 2003, 46:81-86.
26. Costedio M.M., Coates M.D., Brooks E.M., et al. Mucosal serotonin signaling is altered in chronic constipation but not in opiate-induced constipation. Am J Gastroenterol 2010, 105:1173-1180.
27. El-Salhy M., Wendelbo I., Gundersen D. Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease. Mol Med Rep 2013, 8:451-455.
28. Camilleri M. Pharmacological agents currently in clinical trials fordisorders of neurogastroenterology. JClin Invest 2013, 123:4111-4120.
29. Garsed K., Chernova J., Hastings M., et al. Arandomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 2014, 63:1617-1625.
30. Montero-Hadjadje M., Elias S., Chevalier L., et al. Chromogranin A promotes peptide hormone sorting to mobile granules in constitutively and regulated secreting cells: role of conserved N- and C-terminal peptides. JBiol Chem 2009, 284:12420-12431.
31. Öhman L., Stridsberg M., Isaksson S., et al. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms?. Am J Gastroenterol 2012, 107:440-447.
32. El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol 2012, 18:5151-5163.
33. Iacangelo A.L., Eiden L.E. Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept 1995, 58:65-88.
34. Camilleri M. Editorial: fecal granins in IBS-cause or indicator of intestinal or colonic irritation?. Am J Gastroenterol 2012, 107:448-450.
35. Hubel K.A. Intestinal nerves and ion transport: stimuli, reflexes, and responses. Am J Physiol 1985, 248:G261-G271.
36. Playford R.J., Domin J., Beacham J., et al. Preliminary report: role of peptide YY in defense against diarrhoea. Lancet 1990, 335:1555-1557.
37. Bilchik A.J., Hines O.J., Adrian T.E., et al. Peptide YY is a physiological regulator of water and electrolyte absorption in the canine small bowel invivo. Gastroenterology 1993, 105:1441-1448.
38. Bilchik A.J., Hines O.J., Zinner M.J., et al. Peptide YY augments postprandial small intestinal absorption in the conscious dog. Am J Surg 1994, 167:570-574.
39. Liu C.D., Newton T.R., Zinner M.J., et al. Intraluminal peptide YY induces colonic absorption invivo. Dis Colon Rectum 1997, 40:478-482.
40. Moriya R., Shirakura T., Hirose H., et al. NPY Y2 receptor agonist PYY(3-36) inhibits diarrhea by reducing intestinal fluid secretion and slowing colonic transit in mice. Peptides 2010, 31:671-675.
41. Han B. Correlation between gastrointestinal hormones and anxiety-depressive states in irritable bowel syndrome. Exp Ther Med 2013, 6:715-720.
42. Zhang H., Yan Y., Shi R., et al. Correlation of gut hormones with irritable bowel syndrome. Digestion 2008, 78:72-76.
43. Zachos N.C., Tse M., Donowitz M. Molecular physiology of intestinal Na+/H+ exchange. Annu Rev Physiol 2005, 67:411-443.
44. Camilleri M., Carlson P., Acosta A., et al. RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study. Am J Physiol Gastrointest Liver Physiol 2014, 306:G1089-G1098.
45. Linaker B.D., McKay J.S., Higgs N.B., et al. Mechanisms of histamine stimulated secretion in rabbit ileal mucosa. Gut 1981, 22:964-970.
46. Coelho A.M., Fioramonti J., Bueno L. Mast cell degranulation induces delayed rectal allodynia in rats: role of histamine and 5-HT. Dig Dis Sci 1998, 43:727-737.
47. Mobarakeh J.I., Sakurada S., Katsuyama S., et al. Role of histamine H(1) receptor in pain perception: a study of the receptor gene knockout mice. Eur J Pharmacol 2000, 391:81-89.
48. Barbara G., Wang B., Stanghellini V., et al. Mast cell-dependent excitation of visceral nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007, 132:26-37.
49. Buhner S., Li Q., Vignali S., et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009, 137:1425-1434.
50. Klooker T.K., Braak B., Koopman K.E., et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010, 59:1213-1221.
51. van Wanrooij S., Wouters M.M., Van Oudenhove L., et al. Effect of the H1-receptor antagonist ebastin on visceral perception and clinical symptoms in IBS. Gastroenterology 2013, 144(Suppl 1):S160.
52. Bampton P.A., Dinning P.G., Kennedy M.L., et al. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol 2002, 282:G443-G449.
53. Rao A.S., Wong B.S., Camilleri M., et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010, 139:1549-1558.
54. Chadwick V.S., Gaginella T.S., Carlson G.L., et al. Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon. JLab Clin Med 1979, 94:661-674.
55. Gullikson G.W., Cline W.S., Lorenzsonn V., et al. Effects of anionic surfactants on hamster small intestinal membrane structure and function: relationship to surface activity. Gastroenterology 1977, 73:501-511.
56. Alrefai W.A., Saksena S., Tyagi S., et al. Taurodeoxycholate modulates apical Cl-/OH- exchange activity in Caco2 cells. Dig Dis Sci 2007, 52:1270-1278.
57. Kawamata Y., Fujii R., Hosoya M., et al. AG protein-coupled receptor responsive to bile acids. JBiol Chem 2003, 278:9435-9440.
58. Poole D.P., Godfrey C., Cattaruzza F., et al. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil 2010, 22:814-825.
59. Lieu T., Jayaweera G., Bunnett N.W. Gpba: a G protein-coupled receptor for bile acids and an emerging therapeutic target for disorders of digestion and sensation. Br J Pharmacol 2014, 171:1756-1766.
60. Alemi F., Poole D.P., Chiu J., et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 2013, 144:145-154.
61. Wedlake L., A'Hern R., Russell D., et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009, 30:707-717.
62. Camilleri M., Busciglio I., Acosta A., et al. Effect of increased bile Acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea. Am J Gastroenterol 2014, 109:1621-1630.
63. Wingate D.L., Phillips S.F., Hofmann A.F. Effect of glycine-conjugated bile acids with and without lecithin on water and glucose absorption in perfused human jejunum. JClin Invest 1973, 52:1230-1236.
64. Broor S.L., Slota T., Ammon H.V. Cholesterol reduces the effects of dihydroxy bile acids and fatty acids on water and solute transport in the human jejunum. JClin Invest 1980, 65:920-925.
65. Oddsson E., Rask-Madsen J., Krag E. Asecretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea. Scand J Gastroenterol 1978, 13:408-416.
66. Hov J.R., Keitel V., Laerdahl J.K., et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One 2010, 5:e12403.
67. Camilleri M., Shin A., Busciglio I., et al. Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion. Am J Physiol Gastrointest Liver Physiol 2014, 307:G508-G516.
68. Stephen A.M., Haddad A.C., Phillips S.F. Passage of carbohydrate into the colon: direct measurements in humans. Gastroenterology 1983, 85:589-595.
69. Barrett J.S., Gearry R.B., Muir J.G., et al. Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment Pharmacol Ther 2010, 31:874-882.
70. Fukumoto S., Tatewaki M., Yamada T., et al. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol 2003, 284:R1269-R1276.
71. Mitsui R., Ono S., Karaki S., et al. Neural and non-neural mediation of propionate-induced contractile responses in the rat distal colon. Neurogastroenterol Motil 2005, 17:585-594.
72. Karaki S., Kuwahara A. Propionate-induced epithelial K(+) and Cl(-)/HCO3(-) secretion and free fatty acid receptor 2 (FFA2, GPR43) expression in the guinea pig distal colon. Pflugers Arch 2011, 461:141-152.
73. Musch M.W., Bookstein C., Xie Y., et al. SCFA increase intestinal Na absorption by induction of NHE3 in rat colon and human intestinal C2/bbe cells. Am J Physiol Gastrointest Liver Physiol 2001, 280:G687-G693.
74. Treem W.R., Ahsan N., Kastoff G., et al. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: invitro studies of carbohydrate fermentation. JPediatr Gastroenterol Nutr 1996, 23:280-286.
75. Fiskerstrand T., Arshad N., Haukanes B.I., et al. Familial diarrhea syndrome caused by an activating GUCY2C mutation. NEngl J Med 2012, 366:1586-1595.
76. Romi H., Cohen I., Landau D., et al. Meconium ileus caused by mutations in GUCY2C, encoding the CFTR-activating guanylate cyclase 2C. Am J Hum Genet 2012, 90:893-899.
77. + exchangers. Mol Aspects Med 2013, 34:236-251.
78. Pieroni K.P., Bass D. Proton pump inhibitor treatment for congenital chloride diarrhea. Dig Dis Sci 2011, 56:673-676.
79. Binder H.J. Causes of chronic diarrhea. NEngl J Med 2006, 355:236-239.
80. Lok K.H., Hung H.G., Li K.K., et al. Congenital chloride diarrhea: a missed diagnosis in an adult patient. Am J Gastroenterol 2007, 102:1328-1329.
81. Martínez C., Lobo B., Pigrau M., et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut 2013, 62:1160-1168.
82. Martínez C., Vicario M., Ramos L., et al. The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol 2012, 107:736-746.
83. Vazquez-Roque M.I., Camilleri M., Smyrk T., et al. Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea. Am J Physiol Gastrointest Liver Physiol 2012, 303:G1262-G1269.
84. Lamprecht G., Seidler U. The emerging role of PDZ adapter proteins for regulation of intestinal ion transport. Am J Physiol Gastrointest Liver Physiol 2006, 291:G766-G777.